AIMS: This study was conducted to determine whether atenolol was able to decrease BP level and mitigate BP increase during dynamic resistance exercise performed at three different intensities in hypertensives. METHODS:Ten essential hypertensives (systolic/diastolic BP between 140/90 and 160/105mmHg) were blindly studied after 6 weeks of placebo and atenolol. In each phase, volunteers executed, in a random order, three protocols of knee-extension exercises to fatigue: (i) one set at 100% of 1RM; (ii) three sets at 80% of 1RM; and (iii) three sets at 40% of 1RM. Intra-arterial radial blood pressure was measured throughout the protocols. RESULTS:Atenolol decreased systolic BP maximum values achieved during the three exercise protocols (100% = 186 ± 4 vs. 215 ± 7, 80% = 224 ± 7 vs. 247 ± 9 and 40% = 223 ± 7 vs. 252 ± 16mmHg, P < 0.05). Atenolol also mitigated an increase in systolic BP in the first set of exercises (100% =+38 ± 5 vs.+54 ± 9; 80% =+68 ± 11 vs. +84 ± 13 and 40% =+69 ± 7 vs.+84 ± 14, mmHg, P < 0.05). Atenolol decreased diastolic BP values and mitigated its increase during exercise performed at 100% of 1RM (126 ± 6 vs. 145 ± 6 and +41 ± 6 vs.+52 ± 6, mmHg, P < 0.05), but not at the other exercise intensities. CONCLUSIONS:Atenolol was effective in both reducing systolic BP maximum values and mitigating BP increase during resistance exercise performed at different intensities in hypertensive subjects.
RCT Entities:
AIMS: This study was conducted to determine whether atenolol was able to decrease BP level and mitigate BP increase during dynamic resistance exercise performed at three different intensities in hypertensives. METHODS: Ten essential hypertensives (systolic/diastolic BP between 140/90 and 160/105mmHg) were blindly studied after 6 weeks of placebo and atenolol. In each phase, volunteers executed, in a random order, three protocols of knee-extension exercises to fatigue: (i) one set at 100% of 1RM; (ii) three sets at 80% of 1RM; and (iii) three sets at 40% of 1RM. Intra-arterial radial blood pressure was measured throughout the protocols. RESULTS:Atenolol decreased systolic BP maximum values achieved during the three exercise protocols (100% = 186 ± 4 vs. 215 ± 7, 80% = 224 ± 7 vs. 247 ± 9 and 40% = 223 ± 7 vs. 252 ± 16mmHg, P < 0.05). Atenolol also mitigated an increase in systolic BP in the first set of exercises (100% =+38 ± 5 vs.+54 ± 9; 80% =+68 ± 11 vs. +84 ± 13 and 40% =+69 ± 7 vs.+84 ± 14, mmHg, P < 0.05). Atenolol decreased diastolic BP values and mitigated its increase during exercise performed at 100% of 1RM (126 ± 6 vs. 145 ± 6 and +41 ± 6 vs.+52 ± 6, mmHg, P < 0.05), but not at the other exercise intensities. CONCLUSIONS:Atenolol was effective in both reducing systolic BP maximum values and mitigating BP increase during resistance exercise performed at different intensities in hypertensive subjects.
Authors: P Palatini; L Mos; L Munari; F Valle; M Del Torre; A Rossi; L Varotto; F Macor; S Martina; A C Pessina Journal: J Hypertens Suppl Date: 1989-12
Authors: I Pörsti; P Arvola; P Säynävälammi; A K Nurmi; T Metsä-Ketelä; K Koskenvuo; L A Laitinen; V Manninen; H Vapaatalo Journal: Eur J Clin Pharmacol Date: 1990 Impact factor: 2.953
Authors: S C Wu; L Oltrona; M B Secchi; S Mancarella; L Bettazzi; M Civelli; C Sannino; G Loche; G Folli Journal: Minerva Cardioangiol Date: 1989 Jul-Aug Impact factor: 1.347
Authors: Dahan da Cunha Nascimento; Cristiane Rocha da Silva; Renato Valduga; Bruno Saraiva; Ivo Vieira de Sousa Neto; Amilton Vieira; Silvana Schwerz Funghetto; Alessandro Oliveira Silva; Samuel da Cunha Oliveira; Guilherme Borges Pereira; Jeffrey M Willardson; Jonato Prestes Journal: Clin Interv Aging Date: 2018-04-09 Impact factor: 4.458
Authors: Anderson Caetano Paulo; Claudia L M Forjaz; Décio Mion; Giovanio V Silva; Silvana Barros; Valmor Tricoli Journal: Front Physiol Date: 2020-06-29 Impact factor: 4.566